Breakthrough Treatments
UPenn Researchers Block Protein That Helps Parkinson's Spread
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a brain immune protein that may play a major role in the progression of Parkinson's disease. Their findings, published in Neuron, suggest that blocking this protein with monoclonal antibodies could eventually lead to treatments that slow the disease in its earliest stages. The protein, known as glycoprotein nonmetastatic melanoma B (GPNMB), appears to help harmful Parkinson's-related damage spread from one brain cell to another. Scientists found that microglia — the brain's immune cells — are a major source of GPNMB in Parkinson's disease. When neurons become damaged, nearby microglia respond by producing larger amounts of the protein. The research suggests Parkinson's may be driven by a self-reinforcing cycle: alpha-synuclein accumulates in neurons, damaging them. That injury initiates the release of GPNMB, which accelerates the spread of alpha-synuclein, leading to further damage. Using preclinical laboratory experiments with cultured neurons, researchers developed antibodies designed to block GPNMB, which successfully prevented alpha-synuclein pathology from spreading from one cell to another. "Many patients with Parkinson's disease are diagnosed in the early stages, when symptoms are relatively mild, but there is currently no treatment that slows the progression," said lead author Dr. Alice Chen-Plotkin. "These early results are a promising step towards developing this type of treatment." *
$261 Million Investment Announced for Global Parkinson's Research Network
Aligning Science Across Parkinson's (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF), announced $261 million in new grant funding for the Collaborative Research Network (CRN). The funding will support 32 international teams working to map the biological blueprint of Parkinson's disease and build standardized research tools. With this latest round, ASAP's total investment in the CRN since inception exceeds $550 million. The initiative focuses on understanding why Parkinson's varies across individuals — including aging, co-pathologies, and environmental factors — while building tools to improve diagnostics and accelerate personalized therapeutics. Early discoveries have already identified promising druggable targets, with work advancing into pharmaceutical research and clinical development. *
GLP-1 Receptor Agonists: Diabetes Drugs Repurposed for Parkinson's
A growing body of trials suggests that GLP-1 receptor agonists — drugs originally developed for diabetes — may have disease-modifying effects in Parkinson's disease. The medications appear to affect inflammation and cellular metabolism, both implicated in Parkinson's progression. Ongoing studies in 2026 are investigating whether these drugs can slow or halt the disease's advancement rather than simply managing symptoms. *
Stem Cell Research
Doctors Implant Dopamine-Producing Stem Cells in Parkinson's Patients
Scientists are testing whether implanted stem cells can replace the dopamine-producing neurons destroyed by Parkinson's disease. Using stem cell-derived dopamine neurons, researchers are exploring whether transplantation can restore motor function. This approach represents a potential disease-modifying treatment rather than symptom management — a significant departure from current therapies that rely on dopamine replacement drugs or deep-brain stimulation. *
Emerging Research
Van Andel Institute 2026 Grand Challenges in Parkinson's Disease
The Van Andel Institute's 2026 Grand Challenges in Parkinson's Disease conference will focus on convergent mechanisms driving synucleinopathy across model systems and human disease, along with technological and conceptual breakthroughs redefining early diagnosis and treatment. The annual forum brings together leading researchers to discuss the most pressing questions in PD research. *
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.